Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences

Patent metadata

Field	Value
Publication number	US-9567653-B2
Application number	US-201414460285-A
Country	US
Kind code	B2
Filing date	Aug 14, 2014
Priority date	Feb 21, 2002
Publication date	Feb 14, 2017
Grant date	Feb 14, 2017

Abstract

Provided is an isolated mammalian negative strand RNA virus, metapneumovirus (MPV), within the sub-family Pneumoviridae, of the family Paramyxoviridae. Also provided are isolated mammalian negative strand RNA viruses identifiable as phylogenetically corresponding or relating to the genus Metapneumovirus and components thereof. In particular, provided is a mammalian MPV, subgroups and variants thereof. Also provided are genomic nucleotide sequences of different isolates of mammalian MPV, in particular, human MPV. Disclosed is the use of the sequence information of different isolates of mammalian MPV for diagnostic and therapeutic methods. Provided are nucleotide sequences encoding the genome of an MPV or a portion thereof, including both mammalian and avian MPV. Further described are chimeric or recombinant viruses encoded by the nucleotide sequences and chimeric and recombinant mammalian MPV that comprise one or more non-native or heterologous sequences. Also provided are vaccine formulations comprising mammalian or avian MPV, including recombinant and chimeric forms thereof. The vaccine preparations encompass multivalent vaccines, including bivalent and trivalent vaccine preparations.

First claim

What is claimed is:

1. A method for detecting metapneumovirus (MPV) subtype A2 or B2 in a mammalian subject, the method comprising:
contacting a sample from the subject with a probe nucleic acid of at least 10 nucleotides that hybridizes under stringent conditions to a sequence encoding a polypeptide that is at least 90% identical to one of SEQ ID NOs:367 and 369 or the complement of the sequence; and
detecting hybridization of the probe and the target polynucleotide;
wherein the probe does not hybridize under stringent conditions to a sequence encoding a polypeptide of SEQ ID NOs:366 and 368 or the complement of the sequence; and
wherein the stringent conditions include a hybridization buffer comprising 6×SSC and 1 mM EDTA.

2. The method according to claim 1 , wherein the probe nucleic acid comprises at least 25 nucleotides.

3. The method according to claim 1 , wherein the probe nucleic acid comprises at least 40 nucleotides.

4. The method according to claim 1 , wherein detecting hybridization of the probe and the target polynucleotide comprises performing PCR with the probe nucleic acid as a primer.

5. The method according to claim 1 , wherein the mammalian subject is a human.

6. The method according to claim 1 , wherein the probe nucleic acid comprises a detectable marker.

7. The method according to claim 1 , wherein the probe is attached to a solid support.

8. The method according to claim 1 , wherein the target polynucleotide comprises a nucleic acid encoding one of SEQ ID NOs:367 and 369.

9. The method according to claim 1 , wherein the target polynucleotide comprises the complement of a nucleic acid encoding one of SEQ ID NOs:367 and 369.

Assignees

• Univ Erasmus Med Ct Rotterdam

Inventors

• Fouchier Ronaldus Adrianus Maria
• Van Den Hoogen Bernadetta Gerarda
• Osterhaus Albertus Dominicus Marcellinus Erasmus
• De Jong Jan Cornelius
• Groen Jan

Classifications

• A61P7/00

  Drugs for disorders of the blood or the extracellular fluid · CPC title

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P37/04

  Immunostimulants · CPC title

• A61P31/14

  for RNA viruses · CPC title